The World Health Organisation (WHO) has prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a critical tool for safely administering WHO-recommended treatments to prevent relapse of Plasmodium vivax (P. vivax) malaria.
In a statement on Wednesday, WHO emphasised that the decision reflected updated processes designed to enhance efficiency and accessibility of life-saving health solutions globally.
“The prequalification of the G6PD diagnostic test is a significant milestone in ensuring safe and effective P. vivax malaria treatment, reaffirming WHO’s commitment to equitable access to essential health solutions worldwide.
“Each year, approximately 500,000 people die from malaria, with most of the fatalities occurring among children.’”
WHO highlighted that the prequalification of this test followed closely behind the prequalification of two…
Read More
